These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 15987224)

  • 21. The pharmaceutical industry as a medicines provider.
    Henry D; Lexchin J
    Lancet; 2002 Nov; 360(9345):1590-5. PubMed ID: 12443614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimating Drug Costs: How do Manufacturer Net Prices Compare with Other Common US Price References?
    Mattingly TJ; Levy JF; Slejko JF; Onwudiwe NC; Perfetto EM
    Pharmacoeconomics; 2018 Sep; 36(9):1093-1099. PubMed ID: 29752675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Would greater transparency and uniformity of health care prices benefit poor patients?
    Kyle MK; Ridley DB
    Health Aff (Millwood); 2007; 26(5):1384-91. PubMed ID: 17848449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. European prices of newly launched reimbursable pharmaceuticals--a pilot study.
    Martikainen J; Kivi I; Linnosmaa I
    Health Policy; 2005 Nov; 74(3):235-46. PubMed ID: 16226136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of generic drug prices in seven European countries: a methodological analysis.
    Wouters OJ; Kanavos PG
    BMC Health Serv Res; 2017 Mar; 17(1):242. PubMed ID: 28359273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
    Augurzky B; Göhlmann S; Gress S; Wasem J
    Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug makers to cut prices for developing countries.
    AIDS Alert; 1998 Aug; 13(8 Suppl):1-2. PubMed ID: 11365655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects.
    Rand LZ; Kesselheim AS
    Value Health; 2021 Apr; 24(4):473-476. PubMed ID: 33840424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Examining the production costs of antiretroviral drugs.
    Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
    AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Convergence of decision rules for value-based pricing of new innovative drugs.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The price may not be right: the value of comparison shopping for prescription drugs.
    Arora S; Sood N; Terp S; Joyce G
    Am J Manag Care; 2017 Jul; 23(7):410-415. PubMed ID: 28817779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The high cost of medicines in Ireland. Is it time to change the pricing mechanism?
    Tilson L; McGowan B; Bennett K; Barry M
    Eur J Health Econ; 2004 Dec; 5(4):341-4. PubMed ID: 15452737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implications of external price referencing of pharmaceuticals in Middle East countries.
    Kaló Z; Alabbadi I; Al Ahdab OG; Alowayesh M; Elmahdawy M; Al-Saggabi AH; Tanzi VL; Al-Badriyeh D; Alsultan HS; Ali FM; Elsisi GH; Akhras KS; Vokó Z; Kanavos P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):993-8. PubMed ID: 26088919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Compulsory Licensing of Pharmaceuticals in High-Income Countries: A Comparative Analysis.
    Qunaj L; Kaltenboeck A; Bach PB
    Milbank Q; 2022 Mar; 100(1):284-313. PubMed ID: 35257415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 60 Years after Kefauver: Household income required to buy prescription drugs in the United States and abroad.
    Mattingly TJ; Seo D; Ostrovsky AM; Vanness DJ; Conti RM
    Res Social Adm Pharm; 2021 Aug; 17(8):1489-1495. PubMed ID: 33221266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. International price comparisons for pharmaceuticals. Measurement and policy issues.
    Danzon PM; Kim JD
    Pharmacoeconomics; 1998; 14 Suppl 1():115-28. PubMed ID: 10186473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assistive technology pricing in Australia: is it efficient and equitable?
    Summers MP; Verikios G
    Aust Health Rev; 2018 Feb; 42(1):100-110. PubMed ID: 28160784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The level of income appears to have no consistent bearing on pharmaceutical prices across countries.
    Morel CM; McGuire A; Mossialos E
    Health Aff (Millwood); 2011 Aug; 30(8):1545-52. PubMed ID: 21821572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Payers' experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia.
    Morgan SG; Vogler S; Wagner AK
    Health Policy; 2017 Apr; 121(4):354-362. PubMed ID: 28238340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.